Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00040547 | Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) | PHASE1 | COMPLETED | 29 | — | — | Jun 1, 2001 | Feb 1, 2004 | Feb 18, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| Farnesyl Protein Transferase Inhibitor | DRUG | - |
Inclusion: * Male or Female * Measurable or evaluable disease * No more than 2 prior chemotherapy regimens. * Age greater than or equal to 18. * Karnofsky Performance Status greater than or equal to 70%. * Meets protocol requirements for specified laboratory values. * No manifestations of a malabso...